JUN and rheumatoid arthritis: In summary, beta-sitosterol, 16-epi-Isositsirikine, sinomenine, and stepholidine are the main substance bases for the treatment of RA in SA, and PTGS2, JUN, CASP3, and PPARG are the potential targets of action.